No Data
No Data
SSY Group (02005) spent HKD 9.9707 million to repurchase 2.7 million shares on September 12th.
ssy group (02005) announced in a statement that on September 12, 2024, the company invested 9.9707 million...
SSY GROUP: 2024 INTERIM REPORT
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
ssy group (02005.HK) announced that director and chairman Qu Jiguang has increased his shareholding by 1.3 million shares.
According to the latest equity disclosure information from the Hong Kong Stock Exchange, on September 9, 2024, ssy group (02005.HK) executive director, chairman, and CEO Qu Jiguang purchased 1.3 million shares at an average price of HKD 3.8484 per share, with a total investment of approximately HKD 5.0029 million. After the shareholding, Qu Jiguang's latest shareholding amount is 1,127,956,000 shares, and the shareholding ratio has increased from 37.94% to 37.99%.
Need To Know: Analysts Just Made A Substantial Cut To Their SSY Group Limited (HKG:2005) Estimates
SSY Group's Pain Treatment Clears Regulatory Hurdle
No Data
No Data